# Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

> **NCT02789332** · PHASE2 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 107 (actual)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Neoplasms
- HRpos Breast Neoplasms
- BRCA 1 /2 and / or HRD

## Interventions

- **DRUG:** PwO
- **DRUG:** PwCb
- **DRUG:** EC
- **PROCEDURE:** Surgery after neoadjuvant Therapy
- **OTHER:** Stratification

## Key facts

- **NCT ID:** NCT02789332
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2019-02
- **Final completion:** 2020-02
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2020-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02789332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02789332, "Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02789332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*